Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dobutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Dobutamine SCHEMBL9169324 | 1.00 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| (R)-Dobutamine SCHEMBL31681391 | 1.00 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Dobutamine SCHEMBL30094854 | 1.00 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Dobutamine SCHEMBL28350248 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| (R)-Dobutamine SCHEMBL21238 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Levdobutamine SCHEMBL29387828 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Dobutamine SCHEMBL29929447 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Dobutamine SCHEMBL21237 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| (R)-Dobutamine SCHEMBL29690160 | 0.99 | LMNA (1.00) | LMNAKDM4EMAPK1MAPTGMNN | |
| Dobutamine SCHEMBL10816573 | 0.97 | LMNA (0.97) | LMNAKDM4EMAPK1MAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2937 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| CN-120058536-A | Production method of dobutamine hydrochloride | 海南卓科制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119745847-A | Dobutamine hydrochloride medicinal composition and preparation method and application thereof | 上海上药第一生化药业有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119679712-A | Dobutamine hydrochloride injection and preparation method thereof | 海南普利制药股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-116199590-B | Dobutamine hydrochloride and injection thereof | 湖北美林药业有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118831047-A | Composition of dobutamine hydrochloride injection and preparation method thereof | 南京泽恒医药技术开发有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-118724729-A | Preparation method and control method of dobutamine hydrochloride process impurities | 锦州奥鸿药业有限责任公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118340724-A | Dobutamine hydrochloride injection and preparation method thereof | 江苏吴中医药集团有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118221532-A | Synthesis method of dobutamine hydrochloride | 上海现代哈森（商丘）药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-0859635-B1 | STABILISED PHARMACEUTICAL COMPOSITIONS CONTAINING DOBUTAMINE | RHONE POULENC RORER SA (FR) | 1999-04-21 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1996002835-A1 | METHOD AND APPARATUS FOR NON-DESTRUCTIVE ELEMENTAL ANALYSIS OF THE HEADSPACE OF A SEALED CONTAINER | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| EP-0492930-A2 | Transdermal delivery of dobutamine | ELI LILLY AND COMPANY (US) | 1992-07-01 | — | — | EP | claimed |
| US-4581225-A | CARDIOTONIC AGENTS; A CATECHOLAMINE, DOBUTAMINE | ELI LILLY AND COMPANY (US) | 1986-04-08 | — | — | US | claimed |
| EP-0160501-A2 | Sustained release intranasal formulation and method of use thereof | ELI LILLY AND COMPANY (US) | 1985-11-06 | — | — | EP | claimed |
| US-3987200-A | INOTROPIC AGENTS, 3,4-DIHYDROXY-PHENYL-ALKYL PHENETHYLAMINE | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | claimed |